LYCA

33.0704.09%
CH

Chin Hyok Lee

Chief Medical Officer

Dr. Chin Hyok Lee, MD, MPH, serves as Chief Medical Officer at Lycia Therapeutics, Inc. since February 2025. He served as its Chief Medical Officer Allakos Inc. since February 2024 until 2025. Dr. Lee served as Chief Medical Officer of Connect Biopharma Holdings Limited since March 01, 2022 until August 2023. Dr. Lee joined the Connect Biopharma Holdings Limited on March 01, 2022. He has clinical research and development experience in the biopharmaceutical industry. Prior to joining the Company, Dr. Lee served as Vice President of Head of Clinical Science and Chief Medical Officer at Theravance Biopharma, Inc. Before this role, Dr. Lee was Lead Group Medical Director within the Genentech Research & Early Development (gRED) group at Genentech, Inc. Previously, Dr. Lee held roles of increasing responsibility at Eli Lilly & Company, serving most recently as Global Senior Medical Director of Immunology Therapeutic Area, within the Bio-medicines Business Unit and he also served as Associate Medical Director of Immunoscience Group at Abbott. He has successfully led the submission of global regulatory filings, including for U.S. Food and Drug Administration approvals and product commercialization across multiple autoimmune and immunology disease indications. Prior to entering the biopharmaceutical industry, Dr. Lee was on the academic faculty at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.

Positions